WAVE Life Sciences (NASDAQ:WVE) Price Target Raised to $35.00

WAVE Life Sciences (NASDAQ:WVE) had its target price hoisted by Wedbush from $33.00 to $35.00 in a research note issued to investors on Friday,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Other equities research analysts have also issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Wednesday, January 21st. B. Riley Financial boosted their target price on shares of WAVE Life Sciences from $19.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Wells Fargo & Company cut their price target on WAVE Life Sciences from $29.00 to $27.00 and set an “overweight” rating on the stock in a research note on Thursday, February 12th. UBS Group set a $32.00 price target on WAVE Life Sciences in a report on Tuesday, December 16th. Finally, Truist Financial upped their price objective on WAVE Life Sciences from $36.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, WAVE Life Sciences presently has an average rating of “Moderate Buy” and an average price target of $33.13.

WAVE Life Sciences Price Performance

WVE stock opened at $13.12 on Friday. The business’s 50-day moving average is $14.00 and its two-hundred day moving average is $10.96. The firm has a market capitalization of $2.47 billion, a P/E ratio of -10.75 and a beta of -1.77. WAVE Life Sciences has a 1 year low of $5.28 and a 1 year high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%.The company had revenue of $17.25 million for the quarter, compared to analyst estimates of $15.68 million. On average, analysts expect that WAVE Life Sciences will post -1.14 EPS for the current year.

Insider Activity

In related news, insider Chris Francis sold 33,194 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $15.05, for a total transaction of $499,569.70. Following the transaction, the insider owned 61,867 shares in the company, valued at $931,098.35. This trade represents a 34.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Chandra Vargeese sold 3,228 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $43,416.60. Following the completion of the sale, the insider owned 408,246 shares of the company’s stock, valued at approximately $5,490,908.70. This represents a 0.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 111,784 shares of company stock worth $1,910,030 over the last ninety days. 23.98% of the stock is owned by corporate insiders.

Institutional Trading of WAVE Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of WVE. GSK plc acquired a new stake in WAVE Life Sciences during the 4th quarter worth $310,177,000. Darwin Global Management Ltd. acquired a new stake in shares of WAVE Life Sciences during the fourth quarter worth about $125,168,000. Federated Hermes Inc. grew its holdings in shares of WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock worth $27,455,000 after buying an additional 3,750,140 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of WAVE Life Sciences by 83.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock worth $125,927,000 after buying an additional 3,362,880 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after acquiring an additional 2,500,000 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wedbush raised its price target on WVE to $35 and reiterated an “outperform” rating — a bullish signal implying substantial upside versus the current price and likely supporting buy-side interest. Wedbush price target raise
• Positive Sentiment: HC Wainwright increased near-term EPS estimates across Q1–Q4 2026 and kept a “Buy” rating with a $30 target, signaling improving analyst sentiment on WAVE’s financial outlook. (Research note summarized in market coverage.)
• Positive Sentiment: Wave announced acceptance of a late‑breaking oral presentation for WVE‑006 (GalNAc‑RNA editing) at the American Thoracic Society conference — new data from the RestorAATion‑2 trial (400 mg multidose and 600 mg single‑dose cohorts) will be presented, which could materially move the stock depending on the clinical readout. ATS presentation acceptance
• Neutral Sentiment: Analysts’ long‑range earnings expectations were updated in a report setting FY2029 estimates — useful for modeling but unlikely to drive immediate price moves absent near‑term catalysts. Analyst expectations for FY2029
• Negative Sentiment: A CNBC piece highlighted recent FDA reversals and heightened regulatory scrutiny across biotech (citing multiple denials and reversals), which has increased sector volatility and likely weighed on WVE shares despite company‑specific positives — investors are more sensitive to regulatory risk today. FDA reversals raise sector concerns

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.